Syra Health Corp. Class A (SYRA)
OTHER OTC:SYRA
Want to see SYRA full AI Analyst Report?
Top Page
Syra Health Corp. Class A
(OTC:SYRA)
Select Model
Select Model
Rating:64Neutral
Price Target:
$0.46
▲(410.00% Upside)
Action:Downgraded
Date:05/20/26
The score is driven primarily by improving fundamentals (rapid revenue growth, sharply narrowed losses, and positive TTM free cash flow) and conservative leverage. These positives are tempered by still-negative profitability and only neutral-to-mixed technical momentum (below the 20-day average), despite a low P/E that supports valuation.
Positive Factors
Revenue Growth
TTM revenue up ~575% reflects rapid expansion of services and tech adoption across public and behavioral health. Durable top-line growth improves unit economics and creates capacity for margin improvement, supporting a longer-term path to profitability if execution remains consistent.
Negative Factors
Still Unprofitable
Net margin (~-2.4% TTM) and ROE (~-8%) show the company has not yet converted growth into sustainable profitability. Persistent negative returns constrain retained capital, limit ability to self-fund expansion, and require continued margin improvement to secure a durable business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
TTM revenue up ~575% reflects rapid expansion of services and tech adoption across public and behavioral health. Durable top-line growth improves unit economics and creates capacity for margin improvement, supporting a longer-term path to profitability if execution remains consistent.
Read all positive factors
Syra Health Corp. Class A (SYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.13M
Dividend YieldN/A
Average Volume (3M)9.76K
Price to Earnings (P/E)2.7
Beta (1Y)1.10
Revenue Growth-5.51%
EPS Growth95.75%
CountryUS
Employees57
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding11,339,169
10 Day Avg. Volume11,249
30 Day Avg. Volume9,759
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.49
Price to Sales (P/S)0.14
P/FCF Ratio-2.28
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue0.36
Enterprise Value/Gross Profit1.08
Enterprise Value/Ebitda-12.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Syra Health Corp. Class A Business Overview & Revenue Model
Company Description
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, i...
How the Company Makes Money
Syra Health primarily makes money by providing healthcare-related services and solutions to organizational customers (e.g., healthcare entities and public-sector clients). Revenue is generally generated through (1) services engagements, where the ...
Syra Health Corp. Class A Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments such as revenue growth in the Population Health unit and improved operational efficiencies, alongside challenges like NASDAQ delisting, federal contract delays, and a decline in Healthcare Workforce revenue. The balance of achievements and setbacks suggests a cautious outlook.Positive Updates
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Negative Updates
Delisting from NASDAQ
The company announced a strategic decision to voluntarily delist from the NASDAQ capital market to reduce costs and strengthen core fundamentals.
Read all updates
Q1-2025 Updates
Positive
Negative
Revenue Growth
Total revenue for Q1 2025 was $1.9 million, reflecting a 6% annual growth compared to Q1 2024. This growth was primarily driven by strong performance in the Population Health business unit.
Read all positive updates
Company Guidance
During the first quarter of 2025, Syra Health reported positive financial metrics, with total revenue reaching $1.9 million, reflecting a 6% annual growth compared to the same period in 2024. The company achieved a substantial gross margin expansion of 14.6 percentage points, reaching 31.7%, driven by the strong performance of its Population Health business unit, which contributed 65% of total revenue. This unit experienced a 261% year-over-year revenue increase, supported by new contracts and extensions. Despite a 39% reduction in operating expenses, Syra reported a net loss of $472,000, a significant improvement from the $1.4 million loss recorded in the first quarter of 2024. The company also highlighted a strategic shift towards higher-margin, recurring revenue streams and announced the voluntary delisting from NASDAQ to focus on core fundamentals. However, ongoing federal-level changes pose potential challenges, affecting revenue visibility and leading to the withdrawal of previous full-year guidance.Syra Health Corp. Class A Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
72
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.64M | 7.23M | 7.98M | 5.52M | 5.62M | 1.41M |
| Gross Profit | 2.54M | 2.49M | 1.65M | 1.41M | 1.06M | 430.35K |
| EBITDA | -216.89K | -883.86K | -3.68M | -2.84M | -2.07M | -3.07K |
| Net Income | -183.09K | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K |
Balance Sheet | ||||||
| Total Assets | 3.94M | 2.77M | 3.68M | 4.92M | 2.32M | 536.89K |
| Cash, Cash Equivalents and Short-Term Investments | 2.92M | 1.61M | 2.40M | 3.28M | 3.34K | 100.01K |
| Total Debt | 73.09K | 143.79K | 452.08K | 248.10K | 934.84K | 342.86K |
| Total Liabilities | 1.58M | 674.74K | 800.76K | 910.07K | 1.61M | 544.04K |
| Stockholders Equity | 2.36M | 2.10M | 2.88M | 4.01M | 710.10K | -7.15K |
Cash Flow | ||||||
| Free Cash Flow | 755.86K | -447.85K | -2.94M | -2.77M | -2.37M | -94.49K |
| Operating Cash Flow | 755.97K | -447.75K | -2.93M | -2.76M | -2.24M | -88.20K |
| Investing Cash Flow | -107.00 | -107.00 | -11.11K | -15.25K | -121.26K | -6.29K |
| Financing Cash Flow | -324.13K | -332.82K | 2.06M | 6.05M | 2.27M | 191.50K |
Syra Health Corp. Class A Technical Analysis
Positive
0.09
Price Trends
0.36
Positive
0.22
Positive
0.15
Positive
Market Momentum
0.02
Positive
55.85
Neutral
49.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.36, and below the 200-day MA of 0.15, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 55.85 is Neutral, neither overbought nor oversold. The STOCH value of 49.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.
Syra Health Corp. Class A Risk Analysis
Syra Health Corp. Class A disclosed 49 risk factors in its most recent earnings report. Syra Health Corp. Class A reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Syra Health Corp. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $5.13M | 2.67 | -39.06% | ― | -5.51% | 95.75% | |
59 Neutral | $100.31M | 2.07 | 184.97% | ― | -0.87% | 10.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $8.94M | -3.98 | -8.75% | ― | -0.62% | -200.79% | |
46 Neutral | $20.62M | -0.02 | ― | ― | 20.26% | 69.68% | |
46 Neutral | $27.71M | 145.34 | 15.82% | 11.14% | -2.56% | -2181.76% |
* Healthcare Sector Average
SYRA
Syra Health Corp. Class A
0.49
0.40
417.89%
AMS
American Shared Hospital Services
1.35
-1.02
-43.04%
CCM
Concord Medical Services
4.91
-2.14
-30.35%
CCEL
Cryo-Cell International
3.46
-1.37
-28.36%
PIII
P3 Health Partners
13.20
5.94
81.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.